СРАВНЕНИЕ ЭФФЕКТИВНОСТИ РАЗЛИЧНЫХ СХЕМ ЛЕЧЕНИЯ С ПРИМЕНЕНИЕМ АБИРАТЕРОНА АЦЕТАТА И ДОЦЕТАКСЕЛА У ПАЦИЕНТОВ С КАСТРАЦИОННО-РЕФРАКТЕРНЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

Introduction.  In recent years, due to the progressive increase in the prevalence of castration-resistant prostate cancer (CRPC), the question of the sequence of prescription drugs is becoming more acute. Objective  is to compare the effectiveness of various regimens of treatment of CRPC with the use of abirateron acetate and docetaxel.  Materials and methods.  The analysis included 83 patients with CRPC, which were divided into 2 groups depending on the sequence of appointment of abiraterone acetate and docetaxel. Results.  Differences in the level of 2-year survival were statistically insignificant (73,2 % in the 1st group, 69 % in the 2nd group), and 3-year survival significantly differed: in the 1st group – 29,3 %, in the 2nd group – 16,7 % (p <0.05). Due to the short duration of the analysis, 5-year survival was not evaluated. The average value of overall survival in the appointment of the first docetaxel, then abiraterone acetate was 32 months, with the reverse regimen (abiraterone acetate, then docetaxel) – 27 months (p = 0.01). Conclusion .  The scheme with the appointment of the first docetaxel, then abiraterone acetate is more effective from the point of view of affect on overall and 3-year survival in patients with CRPC.